Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore the cutting-edge applications of Surface Plasmon Resonance (SPR) technology in developing HIV-1 Nef inhibitors and PROTAC (Proteolysis Targeting Chimeras) compounds in this 45-minute webinar presented by Dr. Thomas Smithgall, the William S. McEllroy Professor of Biochemistry at the University of Pittsburgh School of Medicine. Learn how SPR serves as a powerful biophysical technique for real-time analysis of biomolecular interactions without the need for labeling, making it invaluable in drug discovery processes. Discover the role of HIV-1 Nef protein as a critical virulence factor and how targeting it represents a novel therapeutic approach for AIDS treatment. Understand the principles behind PROTAC technology, which harnesses the cell's natural protein degradation machinery to selectively eliminate disease-causing proteins. Gain insights into the practical applications of SPR in screening potential inhibitors, characterizing binding kinetics, and optimizing lead compounds for both HIV-1 Nef inhibition and PROTAC development. The presentation draws from Dr. Smithgall's extensive research experience in protein-tyrosine kinase signaling and his work as inventor or co-inventor on six patents related to HIV-1 Nef inhibitor development, providing real-world examples of how SPR technology accelerates the drug discovery pipeline from initial screening to therapeutic development.
